TerminatedPhase 2NCT00608894

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Studying Autoimmune hepatitis

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Veloxis Pharmaceuticals
Principal Investigator: Gerald Y Minuk, M.D.
University of Manitoba Health Sciences Centre, Winnipeg
Intervention: LCP-Tacro (tacrolimus)(drug)
Enrollment: 13 enrolled
Eligibility: 18 years · All sexes
Timeline: 2007 – 2009

Study locations (12)

Mayo Clinic - Phoenix, Phoenix, Arizona, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Northwestern University, Chicago, Illinois, United States
University of Minnesota, Minneapolis, Minnesota, United States
Mayo Clinic, Rochester, Minnesota, United States
Mount Sinai Medical Center, New York, New York, United States
St. Luke's Advanced Liver Therapies, Houston, Texas, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Heritage Medical Research Clinic, Calgary, Alberta, Canada
Zeildler Ledcor Centre, Edmonton, Alberta, Canada
John Buhler Research Centre, University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, Canada
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00608894 on ClinicalTrials.gov

Other trials for Autoimmune hepatitis

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune hepatitis →

← Back to all trials